Antitumor activity of edotecarin in breast carcinoma models

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 2, 2007, Pages 229-235

  Ciomei, Marina ^a   Croci, Valter ^a   Stellari, Fabio ^a   Amboldi, Nadia ^a   Giavarini, Rosa ^a   Pesenti, Enrico ^a  

^a Nerviano Medical Sciences   (Italy)

Author keywords

Capecitabine; DMBA induced mammary model; Docetaxel; Edotecarin; MMTV v Ha ras transgenic model; Xenograft breast models

Indexed keywords

CAPECITABINE; DOCETAXEL; EDOTECARIN; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR MODEL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS;

EID: 34248385768     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0365-8     Document Type: Article

References (24)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168-183
2. Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8:837-855
3. Lavergne O, Lesueur-Ginot L, Pla Rodas F, et al. (1998) Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 41:5410-5419
4. Rothenberg ML, Blanke CD (1999) Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 26:632-639
5. Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1-12
6. Thomas CJ, Rahier NJ, Hecht SM (2004) Camptothecin: current perspectives. Bioorg Med Chem 12:1585-1604
7. Sugimori M, Ejima A, Ohsuki S, et al (1998) Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J Med Chem 41:2308-2318
8. Denny WA (2004) Edotecarin. IDrugs 7:173-177
9. Yoshinari T, Ohkubo M, Fukasawa K, et al (1999) Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 59:4271-4275
10. Meng L, Liao Z, Pommier Y (2003) Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr Top Med Chem 3:305-320
11. Schabel FM Jr, Trader MW, Laster WR Jr, Wheeler GP, Witt MH (1978) Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 23:200-215
12. Ishikawa T, Utoh M, Sawada N, et al. (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
13. Seidman AD, O'Shaughnessy J, Misset JL (2002) Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 7(Suppl 6):20-28
14. Dexter DL, Diamond M, Creveling J, Chen S-F (1993) Chemotherapy of mammary carcinomas arising in ras transgenic mice. Invest New Drugs 11:161-168
15. Bissery MC, Vrignaud P, Lavelle F, Chabot GG (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7:437-460
16. Smith PD, Hilf R, Senior AE (1976) Prolactin binding to mammary gland 7,12-dimethylbenz(a)-anthracene-induced mammary tumors, and liver in rats. Cancer Res 36:3726-3731
17. Arakawa H, Morita M, Kodera T, et al (1999) In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn J Cancer Res 90:1163-1170
18. Inoue K, Fujimoto S, Ogawa M (1983) Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother Pharmacol 10:182-186
19. Komatani H, Kotani H, Hara Y, et al (2001) Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 61:2827-2832
20. Faneyte IF, Kristel PM, Maliepaard M, et al (2002) Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 8:1068-1074
21. Cavailles V, Gompel A, Portois MC, Thenot S, Mabon N, Vignon F (2002) Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J Mol Endocrinol 28(3):165-175
22. Kubota T, Josui K, Fukutomi T, Kitajima M (1995) Growth regulation by estradiol, progesterone and recombinant human epidermal growth factor of human breast carcinoma xenografts grown serially in nude mice. Anticancer Res 15(4):1275-1278
23. Mobbs BG, Johnson IE (1974) Estrogen-binding in vitro by DMBA-induced rat mammary tumors: its relationship to hormone responsiveness. Eur J Cancer 10:757-763
24. Zaccheo T, Giudici D, Lombardi P, di Salle E (1989) A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors. Cancer Chemother Pharmacol 23:47-50